|Articles|February 1, 2003

OTCs stem pharm costs, but the jury's still out on long-term savings

The launch of OTC antihistamines helps plans cut costs, but skeptics argue that accessibility will suffer because of cost barriers

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Subscribe

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

ByPeter Wehrwein, Managing Editor

March 21st 2026

female pharmacist on right looking at computer screen on right | ©Maksym stock.adobe.com

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

ByPeter Wehrwein, Managing Editor

March 19th 2026

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

ByPeter Wehrwein, Managing Editor

Published: March 4th 2026 | Updated: April 8th 2026

tariff spelled out with blocks with letters American flag in the background | ©Andrii

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

ByPeter Wehrwein, Managing Editor

February 23rd 2026

7 things you need to know about the PBM reforms signed into law this week

ByDenise Myshko,Peter Wehrwein, Managing Editor

February 6th 2026

Latest CME

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Multimedia

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

In-Person + Virtual Event

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

October 26, 2026

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Multimedia

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Video

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Video

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Video

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Video

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

OTCs stem pharm costs, but the jury's still out on long-term savings

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

7 things you need to know about the PBM reforms signed into law this week

Latest CME

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

Tennessee Oncology Practice Society

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

20th Annual New York Lung Cancers Symposium®

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Trending on Managed Healthcare Executive

Studies of tafasitamab and epcoritamab

Dosing schedules of combination approaches

A conversation with Julia S. Feldman, Ph.D., about taking impairment and context into consideration when diagnosing preschoolers with ADHD

The connectivity layer payer AI is missing

Review calls for combining outcome measures for hidradenitis suppurativa treatment